Trials / Completed
CompletedNCT02302976
GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The investigators plan to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. Additionally, the investigators plan to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cocaine hydrochloride | |
| DRUG | exenatide | |
| DRUG | placebo |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2014-11-27
- Last updated
- 2023-02-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02302976. Inclusion in this directory is not an endorsement.